Zions Bancorporation National Association UT Cuts Stake in Sanofi $SNY

Zions Bancorporation National Association UT decreased its stake in Sanofi (NASDAQ:SNY) by 33.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,975 shares of the company’s stock after selling 69,047 shares during the period. Zions Bancorporation National Association UT’s holdings in Sanofi were worth $6,465,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of SNY. Financial Consulate Inc. acquired a new position in shares of Sanofi during the third quarter worth $26,000. First Horizon Corp purchased a new position in shares of Sanofi during the 3rd quarter valued at approximately $33,000. Salomon & Ludwin LLC increased its stake in shares of Sanofi by 1,046.3% in the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after buying an additional 701 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Sanofi by 233.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after acquiring an additional 700 shares in the last quarter. Finally, Traub Capital Management LLC bought a new position in Sanofi during the 2nd quarter valued at $51,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY opened at $46.01 on Monday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock’s fifty day moving average is $47.73 and its 200-day moving average is $48.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.29 and a current ratio of 1.09. The firm has a market capitalization of $112.22 billion, a price-to-earnings ratio of 12.78, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45.

Key Stories Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SNY. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Finally, TD Cowen reissued a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. Five equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.